Item 5.02 - Leadership Change: Caroline Dorsa, Chair of the Biogen Inc. Board of Directors, announced on February 11, 2026 that she will not stand for re-election at the 2026 Annual Meeting of Stockholders. Reason for Departure: Ms. Dorsa's decision to not seek re-election was not related to any disagreement with the Board or Company regarding its operations, policies, or practices. Filing Date…

Our analysis rates this filing BULLISH. This 8-K filing discloses a routine, orderly board chair transition with minimal negative implications. Caroline Dorsa's voluntary decision not to seek re-election is explicitly stated as unrelated to any disagreement with the Board or Company. The…

Concern level: LOW (1.8/10).

Notable risk changes: Chair Caroline Dorsa announced non-reelection at 2026 Annual Meeting - departure not related to disagreement with Board; Dr. Maria C. Friere elected as new Board Chair, effective after 2026 Annual Meeting; Leadership transition represents routine governance change with no operational or strategic concerns indicated.

The model predicts BIIB will underperform the S&P 500 by about 0.0% over 30 days (model confidence 85%). This is model analysis for research, not investment advice.